Description

RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neurodegeneration–C57H101N13O17S—Cell Commun Signal. 2023 May 1;21(1):86.|Int J Biol Sci. 2024 Jan 1;20(2):784-800.-[1]Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64.|[2]Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13.–1092460-91-7–1272.56–98.53–CC(C)C[C@@H](C(N)=O)NC([C@H](CCC(O)=O)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@@H](NC(C)=O)CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer; Inflammation/Immunology–H2O : 100 mg/mL (ultrasonic)–Amyloid-β—-Neuronal Signaling–Peptides